Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 366

1.

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group.

Br J Ophthalmol. 2013 Mar;97(3):266-71. doi: 10.1136/bjophthalmol-2012-302391. Epub 2013 Jan 3.

PMID:
23292928
2.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
3.

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.

Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, Houranieh A, Feinberg EB.

Eye (Lond). 2010 Nov;24(11):1708-15. doi: 10.1038/eye.2010.147. Epub 2010 Oct 1.

PMID:
20885427
4.

One-year outcomes of less frequent bevacizumab in age-related macular degeneration.

Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.

Retina. 2011 Apr;31(4):645-53. doi: 10.1097/IAE.0b013e3182012d18.

PMID:
21358363
5.

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.

Ophthalmologica. 2009;223(6):370-5. doi: 10.1159/000227783. Epub 2009 Jul 8.

PMID:
19590252
6.

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.

Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators.

BMJ. 2010 Jun 9;340:c2459. doi: 10.1136/bmj.c2459.

PMID:
20538634
7.

Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.

Hufendiek K, Hufendiek K, Panagakis G, Helbig H, Gamulescu MA.

Int Ophthalmol. 2012 Jun;32(3):259-68. doi: 10.1007/s10792-012-9562-0. Epub 2012 Apr 18.

PMID:
22527448
8.

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.

Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A.

Am J Ophthalmol. 2009 Dec;148(6):875-82.e1. doi: 10.1016/j.ajo.2009.07.009. Epub 2009 Oct 2.

PMID:
19800611
9.

Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.

Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.

Retina. 2007 Apr-May;27(4):432-8.

PMID:
17420694
10.

Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.

Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW Jr.

Retina. 2009 Sep;29(8):1067-73. doi: 10.1097/IAE.0b013e3181b1bb06.

PMID:
19696701
11.

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group.

Ophthalmology. 2013 May;120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014. Epub 2013 Jan 23.

12.

The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.

Aslankurt M, Aslan L, Aksoy A, Erden B, Cekiç O.

Eur J Ophthalmol. 2013 Jul-Aug;23(4):553-7. doi: 10.5301/ejo.5000268. Epub 2013 Mar 20.

13.

Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.

Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.

Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.

PMID:
22414958
14.

Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.

Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, Henschien H, Fossen K, Markovic S, Pedersen TR, Sandvik L, Bragadóttir R.

Ophthalmology. 2016 Jan;123(1):51-9. doi: 10.1016/j.ophtha.2015.09.018. Epub 2015 Oct 21.

PMID:
26477842
15.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group.

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
16.

Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.

Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S.

J Ocul Pharmacol Ther. 2011 Aug;27(4):373-7. doi: 10.1089/jop.2010.0195. Epub 2011 Jun 1.

PMID:
21631366
17.

Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.

Gupta B, Adewoyin T, Patel SK, Sivaprasad S.

Br J Ophthalmol. 2011 Mar;95(3):386-90. doi: 10.1136/bjo.2010.179499. Epub 2010 Aug 6.

PMID:
20693484
18.

One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.

Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J, Pujol O.

Retina. 2011 Jul-Aug;31(7):1261-7. doi: 10.1097/IAE.0b013e318207d152.

PMID:
21499194
19.

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.

Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, Tuomi L.

Ophthalmology. 2012 Jun;119(6):1175-83. doi: 10.1016/j.ophtha.2011.12.016. Epub 2012 Feb 4.

PMID:
22306121
20.

Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.

Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N.

Retina. 2009 Oct;29(9):1235-41. doi: 10.1097/IAE.0b013e3181b20eed.

PMID:
19934818

Supplemental Content

Support Center